Search Clinical Trials
Sponsor Condition of Interest |
---|
Strength After Breast Cancer
MGH Institute of Health Professions
Breast Cancer
The goal of this study is to explore whether a group exercise program called Strength
After Breast Cancer can be delivered in an outpatient physical therapy clinic to improve
physical function among women after treatment for breast cancer.
The main questions this study aims to answer are:
- Ca1 expand
The goal of this study is to explore whether a group exercise program called Strength After Breast Cancer can be delivered in an outpatient physical therapy clinic to improve physical function among women after treatment for breast cancer. The main questions this study aims to answer are: - Can the Strength After Breast Cancer program and the associated outcome battery be successfully delivered in an outpatient physical therapy clinic at Massachusetts General Hospital and do participants find the program practical? - What are the barriers to and facilitators of delivering the group exercise program in a clinical setting and what changes need to be made to the program to improve sustainability and to facilitate implementation at other clinical sites? Participants will complete study questionnaires before and after engaging in the group exercise program and they will participate in interviews following participation in the program. Type: Interventional Start Date: Jan 2024 |
MOLAR: Mapping Oral Health and Local Area Resources
Massachusetts General Hospital
Dental Diseases
The goal of this clinical trial is to test the impact of a screening and linkage
intervention for adverse social determinants of health (aSDoH) on oral health linkage to
care for emergency department patients. Researchers will compare three groups: Patients
in Arm A will receive paper handouts with1 expand
The goal of this clinical trial is to test the impact of a screening and linkage intervention for adverse social determinants of health (aSDoH) on oral health linkage to care for emergency department patients. Researchers will compare three groups: Patients in Arm A will receive paper handouts with general oral health and aSDoH resources. Patients in Arm B will receive paper handouts with geographically-proximate oral health and aSDoH resources. Patients in Arm C will receive geographically-proximate oral health and aSDoH resources plus active navigational assistance. Type: Interventional Start Date: Aug 2023 |
Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF
Jaeb Center for Health Research
Cystic Fibrosis
The goal of the study is to examine multiple markers of anthropometrics, body
composition, sarcopenia and frailty and compare them to dual energy X-ray absorptiometry
(DXA) output, which is considered the current clinical gold-standard tool to measure body
composition. The result of this study will1 expand
The goal of the study is to examine multiple markers of anthropometrics, body composition, sarcopenia and frailty and compare them to dual energy X-ray absorptiometry (DXA) output, which is considered the current clinical gold-standard tool to measure body composition. The result of this study will provide detailed data regarding the nutrition and body composition within this Cystic Fibrosis population and also provide a baseline evaluation for use of these biomarkers in the future studies including evaluation of nutritional intervention. Further, the study will also include psychosocial and other patient-reported outcomes and medical contributors to understand their contributions to the nutritional failure in the adult advanced lung disease population. Finally, the study will evaluate both established and emerging nutritional and body composition parameters and link them to clinical outcomes in adults with CF across the spectrum of pulmonary function. Type: Observational Start Date: Apr 2023 |
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated1
Recursion Pharmaceuticals Inc.
Neurofibromatosis Type 2
This is a two-staged, Phase 2/3, randomized, multi-center study to investigate the
efficacy and safety of REC-2282 in patients with progressive NF2 mutated meningiomas. expand
This is a two-staged, Phase 2/3, randomized, multi-center study to investigate the efficacy and safety of REC-2282 in patients with progressive NF2 mutated meningiomas. Type: Interventional Start Date: Jun 2022 |
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen Ltd
Advanced Cancer
Ovarian Cancer
Lung Cancer
Colon Cancer
Plasma Cell Neoplasm
Phase 1 open label sequential dose escalation and cohort expansion study evaluating the
safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in
combination with COM701 in subjects with advanced malignancies. expand
Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies. Type: Interventional Start Date: Mar 2020 |
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte A1
TopAlliance Biosciences
Advanced Unresectable Solid Tumor
Metastatic Solid Tumor
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy
and in combination with toripalimab in subjects with selected advanced solid
malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose.
The secondary objectives are to: 1) describe the phar1 expand
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004 monotherapy and in combination with toripalimab; and 3) determine the immunogenicity of TAB004 monotherapy and in combination with toripalimab and to determine the immunogenicity of toripalimab when administered with TAB004. The exploratory objectives are to: 1) evaluate pharmacodynamic effects of TAB004 on its target receptor BTLA, as well as effects on the immune system; 2) evaluate biomarkers that may correlate with activity of TAB004 as monotherapy and in combination with toripalimab; 3) evaluate the utility of BTLA ligand, herpesvirus-entry mediator (HVEM), and additional exploratory biomarkers that could aid in selection of appropriate subjects for TAB004 monotherapy and in combination with toripalimab. Type: Interventional Start Date: Oct 2019 |
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subj1
Adaptimmune
Endometrial Cancer
Esophageal Cancer
Esophagogastric Junction (EGJ)
Gastric (Stomach) Cancer
Head and Neck Cancer
This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in
subjects who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor
antigen. Tumor indications include endometrial, esophageal, esophagogastric junction
(EGJ), gastric, head and neck, melanoma, no1 expand
This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen. Tumor indications include endometrial, esophageal, esophagogastric junction (EGJ), gastric, head and neck, melanoma, non-small cell lung (NSCLC), ovarian or urothelial cancer. Type: Interventional Start Date: Aug 2019 |
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
Massachusetts General Hospital
Tumor Surgery
This study is being conducted to decrease the rate of surgical wound complications. The
investigators are studying the effects that caloric restriction has on decreasing the
rate of surgical wound complications. expand
This study is being conducted to decrease the rate of surgical wound complications. The investigators are studying the effects that caloric restriction has on decreasing the rate of surgical wound complications. Type: Interventional Start Date: Jun 2016 |
Building Resiliency in Dyads of Patients With an ANI Admitted to the Neuro-ICU and Their Informal C1
Massachusetts General Hospital
Acute Neurological Injury
Emotional Distress
The purpose of the present investigation is to test the efficacy of a brief (6 sessions)
dyadic (patient and caregiver together) intervention to prevent chronic emotional
distress in at risk dyads admitted to a Neuroscience Intensive Care Unit with an acute
brain injury. Through this study, we seek1 expand
The purpose of the present investigation is to test the efficacy of a brief (6 sessions) dyadic (patient and caregiver together) intervention to prevent chronic emotional distress in at risk dyads admitted to a Neuroscience Intensive Care Unit with an acute brain injury. Through this study, we seek to solve the unmet need of preventing chronic emotional distress in Neuroscience Intensive Care Unit (NICU) dyads through a feasible, acceptable and credible program, and ideally improve the recovery trajectory and dyads' overall quality of life. Type: Interventional Start Date: Dec 2021 |
Virtual Health Insurance Navigation Pilot Program for Colorectal Survivors
Massachusetts General Hospital
Health Insurance
Colorectal Cancer Survivors
This trial aims to assess the feasibility and acceptability of colorectal survivors
approached and engaged in HINT and aims to assess the preliminary efficacy of HINT to
improve 1) health insurance literacy and 2) financial burden related to medical cost
concerns colorectal survivors. The study inv1 expand
This trial aims to assess the feasibility and acceptability of colorectal survivors approached and engaged in HINT and aims to assess the preliminary efficacy of HINT to improve 1) health insurance literacy and 2) financial burden related to medical cost concerns colorectal survivors. The study investigators propose that, compared to the control arm (who will receive a health insurance information guide, but will not receive the navigation intervention), participants in the HINT intervention arm will have improved health insurance literacy and decreased financial distress related to medical costs. Type: Interventional Start Date: Nov 2021 |
PET Fibrin Imaging of DVT and PE
Peter Caravan
Pulmonary Embolism
Deep Vein Thrombosis
Venous Thromboembolism
This study aims to investigate a novel positron emission tomography(PET)-probe for
imaging of fresh intravascular blood clots in pulmonary embolism (PE) and deep venous
thrombosis (DVT). expand
This study aims to investigate a novel positron emission tomography(PET)-probe for imaging of fresh intravascular blood clots in pulmonary embolism (PE) and deep venous thrombosis (DVT). Type: Interventional Start Date: May 2019 |
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
Massachusetts Eye and Ear Infirmary
Differentiated Thyroid Cancer
Advanced Cancer
This research is being done to evaluate the safety and efficacy of neoadjuvant lenvatinib
on surgical outcomes of patients with invasive extrathyroidal differentiated thyroid
cancer (DTC).
This research study involves a study drug called lenvatinib expand
This research is being done to evaluate the safety and efficacy of neoadjuvant lenvatinib on surgical outcomes of patients with invasive extrathyroidal differentiated thyroid cancer (DTC). This research study involves a study drug called lenvatinib Type: Interventional Start Date: Mar 2021 |
Psychosocial Mobile App for Chronic Graft-Versus-Host Disease
Massachusetts General Hospital
Chronic Graft-Versus-Host Disease
Allogeneic Stem Cell Transplant
The purpose of this research study is to see whether a psychosocial mobile app called
Horizons is effective at improving quality of life, symptom burden, psychological
distress, and coping in patients living with chronic graft-versus host disease (GVHD) expand
The purpose of this research study is to see whether a psychosocial mobile app called Horizons is effective at improving quality of life, symptom burden, psychological distress, and coping in patients living with chronic graft-versus host disease (GVHD) Type: Interventional Start Date: Jan 2023 |
An Ethical Approach to Detecting Covert Consciousness
Massachusetts General Hospital
Disorder of Consciousness
This study aims to develop an ethical approach to developing and deploying novel
neurotechnologies to aid in the detection of consciousness and prediction of recovery
after brain injury. expand
This study aims to develop an ethical approach to developing and deploying novel neurotechnologies to aid in the detection of consciousness and prediction of recovery after brain injury. Type: Observational Start Date: Feb 2022 |
Epidermal Skin Grafts to Improve Healing In Radiation Wounds
Massachusetts General Hospital
Radiation Dermatitis
Patients undergoing radiation for the treatment of malignancies may suffer from side
effects to the skin in the form of radiation dermatitis. This can lead to local wound
formation with poor healing. Treatment options for the resulting wound can range from
watchful waiting to more aggressive debrid1 expand
Patients undergoing radiation for the treatment of malignancies may suffer from side effects to the skin in the form of radiation dermatitis. This can lead to local wound formation with poor healing. Treatment options for the resulting wound can range from watchful waiting to more aggressive debridement and secondary grafting. Epidermal grafting is a technique in which autologous epidermis is used to cover wounds that are larger than the donor site. Previous studies have demonstrated that this is an effective treatment for different wounds and ulcers but its utility has not yet been evaluated for the treatment of radiation induced injuries. The CelluTome Epidermal Grafting System is a semi automated device that allows easy formation of epidermal Blister. Our study will evaluate the efficacy of epidermal grafts collected using the CelluTome device in the treatment of radiation dermatitis. Type: Interventional Start Date: Jan 2021 |
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
Massachusetts General Hospital
Dyspepsia
Gastroparesis
Explore the effects of auricular transcutaneous vagal nerve stimulation (taVNS) on brain
and stomach outcomes in functional dyspepsia and gastroparesis patients. expand
Explore the effects of auricular transcutaneous vagal nerve stimulation (taVNS) on brain and stomach outcomes in functional dyspepsia and gastroparesis patients. Type: Interventional Start Date: Nov 2018 |
Stroke Motor Rehabilitation and Recovery Study
Massachusetts General Hospital
Stroke, Ischemic
SMaHRT (Stroke Motor reHabiliation and Recovery sTudy) is a longitudinal study aimed at
understanding the natural history of upper extremity motor recovery after ischemic and
hemorrhagic stroke. expand
SMaHRT (Stroke Motor reHabiliation and Recovery sTudy) is a longitudinal study aimed at understanding the natural history of upper extremity motor recovery after ischemic and hemorrhagic stroke. Type: Observational Start Date: Jun 2017 |
Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF)
Massachusetts General Hospital
Iron-deficiency
Heart Failure With Preserved Ejection Fraction
The primary objective of this study is to determine if the correction of functional iron
deficiency by administering a single dose of intravenous iron (ferric derimaltose or
Monoferric®) in participants with heart failure with preserved ejection fraction (HFpEF)
will improve exercise capacity as me1 expand
The primary objective of this study is to determine if the correction of functional iron deficiency by administering a single dose of intravenous iron (ferric derimaltose or Monoferric®) in participants with heart failure with preserved ejection fraction (HFpEF) will improve exercise capacity as measured by the change in peak oxygen uptake (peak VO2) from baseline to 12 weeks. Type: Interventional Start Date: Nov 2021 |
Mindfulness and Behavior Change to Improve Cardiovascular Health of Older People With HIV
Massachusetts General Hospital
Hiv
Cardiovascular Diseases
Older people with HIV (OPWH) are disproportionately impacted by cardiovascular disease
(CVD) attributable to behavioral risk factors, and chronic HIV immune dysregulation
resulting inflammation. Systemic inflammation is exacerbated by psychological distress
via activating the immune response and dr1 expand
Older people with HIV (OPWH) are disproportionately impacted by cardiovascular disease (CVD) attributable to behavioral risk factors, and chronic HIV immune dysregulation resulting inflammation. Systemic inflammation is exacerbated by psychological distress via activating the immune response and driving pro-inflammatory CVD risk behaviors. There is promising evidence to suggest that mindfulness could be an effective intervention to reduce psychological distress and support behaviorally- and inflammatory-mediated CVD risk reduction. This project aims to refine and synthesize mindfulness and behavior change content from evidence-based protocols (mindfulness-based stress reduction and diabetes prevention program) to develop and pilot test a new text message-enhanced intervention called "One Mind One Heart" (OM-OH) using feedback from semi-structured interviews with OPWH in psychological distress (N=20), and my multidisciplinary mentorship team (Aim 1). An open pilot (N=5) with exit interviews and pre-post self-report assessments, will inform the initial acceptability of OM-OH and further refine OM-OH as needed (Aim 2). Finally, a pilot randomized controlled trial (RCT; N=50) will be conducted to a.) evaluate benchmarks of feasibility and acceptability of study methods and refined OM-OH compared to enhanced usual care, and b.) investigate potential for effects on psychological distress, inflammation, and behavioral CVD risk (Aim 3). Findings will provide the foundation for an R01 application to conduct an efficacy trial of OM-OH to reduce inflammatory-mediated CVD risk among OPWH. Type: Interventional Start Date: Sep 2023 |
Low-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorde1
University of California, Los Angeles
Generalized Anxiety Disorder
There are few treatment options available for patients once they have failed standard
psychopharmacological therapy for generalized anxiety disorder. Existing brain
stimulation methods such as rTMS fail to target deep brain structures associated with
anxiety disorders; structures such as the amygda1 expand
There are few treatment options available for patients once they have failed standard psychopharmacological therapy for generalized anxiety disorder. Existing brain stimulation methods such as rTMS fail to target deep brain structures associated with anxiety disorders; structures such as the amygdala. In this double-blind sham-controlled clinical trial, the investigators propose to establish baseline severity of anxiety in 48 patients, then deliver eight treatments over four sessions of focused ultrasound stimulation to the amygdala. Anxiety severity will be assessed using standard psychometric scales after each session, and at follow-ups. Type: Interventional Start Date: Jul 2021 |
The Boston Pace Study
Massachusetts General Hospital
Left Bundle Branch Area Pacing
Right ventricular (RV) pacing can cause left ventricular systolic dysfunction in 10- 20%
of patients. Biventricular pacing had previously been shown to prevent left ventricular
systolic dysfunction. However, implantation of coronary sinus lead increases procedural
risk and can be limited by higher1 expand
Right ventricular (RV) pacing can cause left ventricular systolic dysfunction in 10- 20% of patients. Biventricular pacing had previously been shown to prevent left ventricular systolic dysfunction. However, implantation of coronary sinus lead increases procedural risk and can be limited by higher threshold and phrenic nerve capture. HIS pacing has been evaluated as an alternative pacing strategy, but its routine use was limited by difficulty of the procedure, success rate and high pacing threshold. Left bundle branch area pacing (LBBAP) is a promising physiologic pacing technique that has been proposed as a pacing strategy to prevent pacing induced cardiomyopathy and for treatment of desynchrony in heart failure. LBBAP has been adopted widely and performed routinely on patients with AV block. Currently, it is up to the discretion of the proceduralist whether LBBAP is performed given that there is lack of evidence to guide pacing strategies. Type: Interventional Start Date: May 2023 |
Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias
University of Florida
Spinocerebellar Ataxia Type 1
Spinocerebellar Ataxia Type 2
Spinocerebellar Ataxia Type 3
Spinocerebellar Ataxia Type 6
Spinocerebellar ataxias (SCA) are genetic neurological diseases that cause imbalance,
poor coordination, and speech difficulties. There are different kinds of SCA and this
study will focus on types 1, 2,3, and 6 (SCA 1, SCA 2, SCA 3 , also known as
Machado-Joseph disease and SCA 6). The diseases ar1 expand
Spinocerebellar ataxias (SCA) are genetic neurological diseases that cause imbalance, poor coordination, and speech difficulties. There are different kinds of SCA and this study will focus on types 1, 2,3, and 6 (SCA 1, SCA 2, SCA 3 , also known as Machado-Joseph disease and SCA 6). The diseases are rare, slowly progressive, cause increasingly severe neurological difficulties and are variable across and within genotypes. The purpose of this research study is to bring together a group of experts in the field of SCA for the purpose of learning more about the disease. The research questions are: 1. How does your disease progress over time? 2. What are the best ways to measure the progression? 3. Do some genes, other than the gene that is abnormal in your disease, have any effect on the way the disease behaves? This is a nationwide study and we expect that 800 patients will participate all over the USA. The participants will be in the study for an indeterminate period of time. Study visits will be done every 6 or 12 months depending on the participating site. Type: Observational Start Date: Apr 2010 |
Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merke1
Kartos Therapeutics, Inc.
Merkel Cell Carcinoma
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the
treatment of patients with Merkel Cell Carcinoma (MCC) who have failed treatment with at
least one anti-PD-1 or anti-PD-L1 immunotherapy or in combination with avelumab in MCC
patients who are anti-PD-1 or anti-PD-1 expand
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel Cell Carcinoma (MCC) who have failed treatment with at least one anti-PD-1 or anti-PD-L1 immunotherapy or in combination with avelumab in MCC patients who are anti-PD-1 or anti-PD-L1 treatment naïve. Inhibition of MDM2 is a novel mechanism of action in MCC. Type: Interventional Start Date: Mar 2019 |
Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognosti1
Dana-Farber Cancer Institute
Mesothelioma
This research study is evaluating a new method for determining stage and prognosis of
individuals with malignant pleural mesothelioma. expand
This research study is evaluating a new method for determining stage and prognosis of individuals with malignant pleural mesothelioma. Type: Interventional Start Date: Oct 2018 |
Electronic Physician Notification to Facilitate the Recognition and Management of Severe Aortic Ste1
Massachusetts General Hospital
Aortic Stenosis
The DETECT AS Trial is a randomized clinical trial and quality improvement initiative
that seeks to investigate the impact of electronic provider notification of severe aortic
stenosis (AS) on its management, on the utilization of aortic valve replacement (AVR),
and on ethnic and racial disparities1 expand
The DETECT AS Trial is a randomized clinical trial and quality improvement initiative that seeks to investigate the impact of electronic provider notification of severe aortic stenosis (AS) on its management, on the utilization of aortic valve replacement (AVR), and on ethnic and racial disparities in AVR utilization. After the investigators identify patients in whom echocardiography shows severe aortic stenosis, defined by an aortic valve area (AVA) <1.0cm2, the ordering provider of the echocardiogram will then be randomly assigned to either the intervention group or to the control group. Providers randomly assigned to the intervention group will be sent an electronic (email or message via the electronic health record) physician notification for every one of their patients with severe aortic stenosis on TTE. Electronic notification will also highlight relevant ACC/AHA Clinical Practice Guideline recommendations regarding the management of severe AS. No intervention will be performed for patients belonging to physicians assigned to the control group. The primary endpoint will be AVR utilization, defined as the proportion of patients with a clinical indication for severe AS that undergo AVR. Clinical indications will be based upon the 2020 AHA/ACC Clinical Practice Guidelines for Valvular Heart Disease. Secondary end-points will be mortality, heart failure hospitalization, TTE utilization/surveillance, AS billing code diagnosis, and cardiology/Heart Valve Team referral. Pre-defined subgroup analyses will be performed to assess AVR utilization among women, racial/ethnic minority groups, low-gradient AS, cardiologist and non-cardiologist ordering provider, and inpatient and outpatient practice settings. Type: Interventional Start Date: Feb 2022 |
- Previous
- Next